<?xml version="1.0" encoding="UTF-8"?>
<p>Fundamentally, what the field really lacks is a selective ASIC3 antagonist that effectively blocks both transient and sustained phases of the current (as well as those derived from ASIC3 heteromers), which could be used in an interventional way to determine the true contribution of ASIC3 to pain and other physiology, and the quest for such a compound remains.</p>
